BioLine Rx Ltd (BLRX)

1.10
0.01 0.92
NASDAQ : Health Care
Prev Close 1.09
Open 1.09
Day Low/High 1.07 / 1.14
52 Wk Low/High 0.71 / 2.25
Volume 561.57K
Avg Volume 588.20K
Exchange NASDAQ
Shares Outstanding 104.10M
Market Cap 113.47M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioLineRx To Report Second Quarter 2017 Results On August 8, 2017

BioLineRx To Report Second Quarter 2017 Results On August 8, 2017

Management to hold conference call at 10:00 a.m. EDT

BioLineRx Announces Initiation Of Phase 1b/2 Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration

BioLineRx Announces Initiation Of Phase 1b/2 Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration

Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations

BioLineRx Announces Regulatory Submission For Phase 1b Trial Of BL-8040 In Combination With Atezolizumab In AML

Phase 1b trial under cancer immunotherapy collaboration with Genentech

BioLineRx To Report First Quarter 2017 Results On May 25, 2017

Management to hold a conference call at 10:00 a.m. EDT

BioLineRx Announces Acquisition Of Agalimmune Ltd. To Accelerate Expansion Of Immuno-Oncology Pipeline

Agalimmune's Lead Asset, AGI-134, Provides a Unique Approach for Eliciting Patient-specific, Anti-tumor Immune Responses in Multiple Cancer Types

BioLineRx To Report Annual 2016 Results On March 23, 2017

Management to hold a conference call at 9:00 a.m. EDT

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) signed a licensing agreement with two Israeli companies to allow the development of a drug that treats liver failure conditions.

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions...

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific...

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast...

BioLineRx To Present At The LD Micro Main Event

BioLineRx To Present At The LD Micro Main Event

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third...

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited...

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive results from the dose...

BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration

BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Omega Pharma,...

BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York

BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Reports Second Quarter 2015 Financial Results

BioLineRx Reports Second Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the...

BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a Phase 2b...